TY2B-DR3 Antibody

What is DR3 and why are antibodies against it important in immunological research?

DR3 (Death Receptor 3), also known as TNFRSF25, Apo-3, WSL-1, TRAMP, LARD, and TR3, is a member of the TNF-receptor superfamily that plays crucial roles in immune regulation. DR3 is expressed preferentially in lymphocyte-rich tissues and is involved in regulating lymphocyte homeostasis through stimulation of NF-kappa B activity and regulation of cell apoptosis .

DR3 antibodies are valuable research tools because they enable investigation of this receptor's role in T cell development, activation, and maintenance of immune tolerance. The ability to target DR3 allows researchers to study pathways involved in apoptosis mediation and NF-κB signaling, which are essential for immune response regulation and homeostasis maintenance . Notably, DR3 contains a unique death domain that triggers apoptotic signaling, making antibodies against it particularly useful for studying programmed cell death in immune contexts .

What are the key characteristics of DR3 antibodies commonly used in research?

Several DR3 antibodies have been developed for research applications, each with specific characteristics. The JD3 monoclonal antibody reacts with human DR3 and has been extensively tested for flow cytometric analysis of normal human peripheral blood cells and DR3-transfected cells . This antibody typically demonstrates greater than 90% purity as determined by SDS-PAGE and less than 10% aggregation as determined by HPLC .

Another well-characterized antibody is the B-8 DR3 antibody, a mouse monoclonal IgG2b kappa light chain antibody that detects DR3 protein across multiple species (mouse, rat, and human). This versatile antibody can be used in western blotting, immunoprecipitation, immunofluorescence, immunohistochemistry, and ELISA applications . These antibodies are available in various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates, providing flexibility for different experimental approaches .

How do agonistic DR3 antibodies influence regulatory T cell populations?

Agonistic DR3 antibodies (αDR3) have been demonstrated to selectively expand regulatory T cells (Tregs) in vivo. Research has shown that a single dose of αDR3 significantly increases both the proportion and absolute numbers of Tregs in lymph nodes and spleen . This expansion is selective, as demonstrated by upregulation of the proliferation marker Ki67 primarily in the FoxP3+ CD4+ central memory T-cell subset .

The mechanism of DR3-induced Treg expansion requires T-cell receptor (TCR), IL-2, and MHC II signaling, though the complete pathway is not fully understood . Importantly, Tregs expanded through αDR3 treatment maintain their suppressive function, with evidence suggesting enhanced functionality even at lower Treg frequencies from αDR3-treated donors compared to controls . This selective expansion of functional Tregs has significant implications for research on autoimmunity, transplantation, and inflammatory conditions.

What are the optimal protocols for using DR3 antibodies in flow cytometric analysis?

For flow cytometric analysis using DR3 antibodies such as JD3, optimal protocols typically involve using ≤1 μg of antibody per test, where a test is defined as the amount of antibody needed to stain a cell sample in a final volume of 100 μL . Cell numbers can range from 10^5 to 10^8 cells per test, though researchers should determine the optimal cell concentration empirically for their specific experimental system .

For comprehensive analysis of DR3 expression across heterogeneous T cell populations, advanced analytical approaches such as Spanning-tree Progression Analysis of Density-normalized Events (SPADE) can be employed. This method allows for objective analysis of high-dimensional flow cytometry data and visualization of how surface and intracellular molecules behave across entire cell populations . When utilizing conjugated DR3 antibodies, appropriate compensation controls should be included to account for spectral overlap between fluorophores.

How can agonistic DR3 antibodies be utilized in transplantation research models?

Agonistic DR3 antibodies have shown significant utility in transplantation research, particularly in models studying graft-versus-host disease (GVHD). In bone marrow transplantation (BMT) models, donor treatment with αDR3 (typically administered by intraperitoneal injection at 0.5 mg/kg, 4 days before transplantation) results in selective expansion of Tregs and reduced activation of conventional T cells .

When T cells from αDR3-treated donors are transferred to recipient animals, they demonstrate significantly reduced proliferation in response to allogeneic stimuli compared to T cells from isotype-treated controls . This reduced proliferative capacity correlates with maintained higher Treg frequencies in recipient animals receiving cells from αDR3-treated donors . Importantly, while αDR3 treatment reduces acute GVHD, it preserves graft-versus-tumor (GVT) effects, making this approach particularly valuable for studying the balance between GVHD and GVT in transplantation research .

What methodologies are effective for studying DR3's role in intestinal epithelial homeostasis?

Research into DR3's role in intestinal epithelial cells (IECs) during homeostasis, tissue injury, and regeneration has employed several methodologies. Knockout mouse models (Dr3-/- mice) have been particularly valuable for understanding DR3's function in this context . These models allow researchers to assess the impact of DR3 deficiency on intestinal tissue repair by examining histological parameters such as regeneration subscores .

When investigating the immunological impact of DR3 in intestinal contexts, researchers commonly assess cell numbers and cytokine expression profiles, including interferon gamma (IFN-gamma), interleukin (IL)17A, IL22, and IL10 . Flow cytometric analysis of regulatory T cell populations, particularly FoxP3+ Tregs in mesenteric lymph nodes (MLNs), provides insights into how DR3 influences local immune regulation in the intestinal environment . These methodologies collectively enable a comprehensive assessment of DR3's multifaceted roles in intestinal homeostasis and repair mechanisms.

How can DR3 antibodies be used to investigate apoptotic signaling pathways?

DR3 antibodies provide powerful tools for investigating apoptotic signaling pathways due to DR3's role as a death receptor that mediates programmed cell death. For studying DR3-mediated apoptosis, researchers can employ multiple complementary techniques. Western blotting with DR3 antibodies such as B-8 can detect changes in DR3 expression levels under different experimental conditions .

To study the interaction between DR3 and its downstream signaling components, immunoprecipitation using DR3 antibodies can isolate DR3-containing protein complexes for further analysis . This approach is particularly valuable for identifying novel binding partners or characterizing known interactions with death domain-containing adaptor proteins that mediate DR3's apoptotic signaling .

For visualization of DR3 localization during apoptotic processes, immunofluorescence techniques using DR3 antibodies enable researchers to track receptor distribution and clustering in response to various stimuli . Combining these approaches with assessments of cell viability, caspase activation, and other apoptotic markers provides a comprehensive view of DR3's role in programmed cell death pathways.

What techniques are most effective for studying the impact of DR3 signaling on NF-κB activation?

To investigate DR3's role in NF-κB pathway activation, researchers can employ several sophisticated techniques. Agonistic DR3 antibodies can be used to stimulate cells, followed by assessment of NF-κB activation through electrophoretic mobility shift assays (EMSA) or luciferase reporter assays containing NF-κB response elements .

Immunoblotting for phosphorylated IκB kinase (IKK) complex components and degradation of IκBα provides direct evidence of canonical NF-κB pathway activation following DR3 stimulation . For more comprehensive analysis, chromatin immunoprecipitation (ChIP) assays using antibodies against NF-κB subunits (p65, p50) after DR3 stimulation can identify specific gene targets regulated by this signaling axis.

Advanced researchers might combine these approaches with RNA-seq or proteomics to characterize the full spectrum of transcriptional and translational changes induced by DR3-mediated NF-κB activation. These multifaceted approaches enable detailed mapping of the signaling networks connecting DR3 engagement to NF-κB-dependent gene expression programs controlling immune cell function and survival.

How do DR3 antibodies contribute to understanding T cell development and homeostasis?

DR3 antibodies have provided crucial insights into T cell development and homeostasis, particularly through their use in studying knockout models and Treg dynamics. Knockout studies in mice have suggested that DR3/TNFRSF25 plays an important role in the removal of self-reactive T cells in the thymus, highlighting its contribution to central tolerance mechanisms .

For investigating DR3's impact on T cell population dynamics, researchers can employ DR3 antibodies in conjunction with BrdU incorporation studies to measure proliferation rates of different T cell subsets. This approach has revealed that significantly fewer conventional T cells proliferate when derived from αDR3-treated donors compared to those from isotype-treated controls .

Studies of Treg maintenance in peripheral tissues have demonstrated that recipient mice receiving T cells from αDR3-treated donors maintain higher Treg proportions over extended periods (up to 14 days post-transfer) . This persistence suggests that DR3 signaling influences not only acute T cell responses but also establishes lasting changes in T cell homeostatic mechanisms.

What are optimal titration strategies for DR3 antibodies in different applications?

Proper titration of DR3 antibodies is critical for obtaining reliable, reproducible results across different experimental applications. For flow cytometry applications, it is recommended that DR3 antibodies like JD3 be carefully titrated for optimal performance, starting from concentrations of ≤1 μg per test and adjusting based on signal-to-noise ratio .

When conducting in vivo experiments with agonistic DR3 antibodies, researchers typically administer 0.5 mg/kg via intraperitoneal injection, with timing dependent on the experimental design (e.g., 4 days before cell isolation or transplantation) . This dosage has been demonstrated to effectively expand Tregs without causing significant adverse effects.

For immunohistochemistry or immunofluorescence applications using antibodies like DR3 B-8, initial titrations should typically range from 1:50 to 1:500 dilutions of antibody stock solutions, with optimization based on signal intensity and background levels . Western blotting applications may require different optimal concentrations, and researchers should perform dilution series to determine ideal antibody concentrations for specific experimental conditions and detection methods.

What controls should be included when using DR3 antibodies in research?

Proper experimental controls are essential when working with DR3 antibodies. For flow cytometry, isotype controls matching the DR3 antibody's isotype (e.g., IgG2b kappa for B-8) should be included to assess non-specific binding . Additionally, negative cell populations known not to express DR3 and positive controls with confirmed DR3 expression should be included to validate staining specificity.

In functional studies using agonistic DR3 antibodies, isotype-treated animals or cells serve as critical controls for comparing treatment effects . When studying Treg expansion, researchers should assess both the proportion and absolute numbers of Tregs to obtain a complete picture of the antibody's impact .

For immunoprecipitation experiments, pre-clearing samples with an irrelevant antibody of the same isotype helps reduce non-specific binding . In all applications, blocking with appropriate sera or proteins before antibody application can minimize background and increase signal specificity. These comprehensive control strategies ensure that observed effects are specifically attributable to DR3 targeting rather than experimental artifacts.

How should researchers address potential cross-reactivity issues with DR3 antibodies?

Cross-reactivity is an important consideration when working with DR3 antibodies, particularly given DR3's multiple aliases (Apo-3, WSL-1, TRAMP, LARD, DDR3, and TR3) and its membership in the TNF-receptor superfamily, which contains structurally similar proteins . To address potential cross-reactivity issues, researchers should first validate antibody specificity using cells from DR3 knockout models as negative controls .

For applications requiring high specificity, pre-absorption of the antibody with recombinant DR3 protein can help confirm binding specificity. Additionally, testing the antibody against cell lines transfected with DR3 versus related TNF-receptor family members can help establish the antibody's specificity profile .

When studying DR3 in multi-species contexts, researchers should verify species cross-reactivity experimentally rather than relying solely on manufacturer claims. While some antibodies like B-8 are reported to detect DR3 across mouse, rat, and human samples , species-specific differences in epitope structure may affect binding efficiency and should be validated for each experimental system.

How should researchers quantify and interpret Treg expansion following agonistic DR3 antibody treatment?

Quantification of Treg expansion following agonistic DR3 antibody treatment should involve multiple complementary measurements. Both the proportion of Tregs within the CD4+ T cell population and absolute Treg numbers should be assessed, as these parameters provide different but equally important information about the antibody's effects . Flow cytometric analysis should include staining for CD4, CD25, and FoxP3 to accurately identify the Treg population.

For comprehensive analysis of heterogeneous T cell responses to DR3 stimulation, advanced analytical approaches like SPADE can provide valuable insights. This method enables visualization of how markers like FoxP3 and proliferation indicators (Ki67) are distributed across different T cell subsets defined by markers such as CD4, CD8, CD44, and CD62L .

When interpreting Treg expansion data, researchers should consider not only the quantitative changes but also functional capacity. Suppression assays comparing Tregs from αDR3-treated versus control animals at various Treg:T cell ratios can reveal whether DR3 stimulation enhances Treg suppressive function in addition to expanding their numbers . This functional assessment is critical for understanding the biological significance of DR3-mediated Treg expansion.

What are the key considerations when analyzing conflicting results from DR3 antibody experiments?

When analyzing conflicting results from DR3 antibody experiments, several factors should be considered. First, the specific clone and format of DR3 antibody used can significantly impact experimental outcomes. Different antibodies (e.g., JD3 versus B-8) may recognize different epitopes on DR3, potentially activating distinct downstream signaling pathways .

The cellular context is also crucial, as DR3's effects vary across different cell types. For instance, while DR3 was initially thought to be a receptor for TWEAK, subsequent studies showed that TWEAK could induce apoptosis via receptors distinct from DR3 . This highlights the importance of considering receptor-ligand specificity when interpreting experimental results.

Timing of observations is another critical factor, as DR3-mediated effects on cell populations like Tregs may change over time. Studies tracking Treg frequencies have shown that while control animals experience rapid decreases in Treg proportions early after BMT, αDR3-treated animals maintain higher Treg proportions over extended periods . Thus, apparent conflicts in results may reflect differences in experimental timelines rather than genuine contradictions.

How can researchers distinguish between direct and indirect effects of DR3 antibody treatment?

Distinguishing between direct and indirect effects of DR3 antibody treatment requires careful experimental design and analysis. In vivo, αDR3 treatment affects multiple cell populations simultaneously. To delineate direct from indirect effects, researchers can employ cell type-specific DR3 knockout models or perform adoptive transfer experiments with defined cell populations .

In vitro assays using purified cell populations can help identify direct effects of DR3 antibody treatment. For example, studies have shown that αDR3-expanded Tregs maintain suppressive function in mixed lymphocyte reaction (MLR) assays, suggesting a direct enhancement of Treg functionality . Comparing the timing of different cellular responses can also provide insights into causality – rapidly occurring changes are more likely to represent direct effects, while delayed responses may reflect indirect consequences.

Mechanistic studies investigating the dependence of observed effects on specific signaling pathways can further clarify direct versus indirect mechanisms. For instance, the finding that DR3-induced Treg expansion requires TCR, IL-2, and MHC II signaling suggests a complex mechanism involving multiple pathways . By systematically blocking these pathways, researchers can delineate the direct targets of DR3 signaling from downstream consequences.